Bahar Dasgeb, MD

Pictured: Dasgeb Bahar

I am a board certified physician-scientist with dual residency training in dermatology and nuclear medicine-molecular imaging. My clinical focus is on pigmented skin neoplasms including atypical moles (dysplastic nevi) and melanoma. My other clinical interests include non-melanoma skin cancers (e.g., basal cell carcinoma and squamous cell carcinoma), and consultative dermatology.

I have completed a fellowship at Memorial Sloan Kettering and the National Institutes of Health (NIH) in biophotonics with an emphasis on development of theranostics (probes that are both diagnostic and therapeutic) for skin cancer. My efforts led a joint MSK/NIH interdisciplinary translational project to develop a theranostic probe to molecularly target basal cell carcinoma (BCC). The goal of the project is to develop a non-invasive technology to molecularly image, diagnose, and treat BCC. If successful, this approach will also be applicable to other types of skin cancers. In my current dual capacity as a member of the Memorial Sloan Kettering faculty and an invited scientist at the NIH, my research efforts continue to focus on molecular imaging of skin cancer, with a recent emphasis on the use of nano-sized (less than 100 nanometers) probes to target biomarkers specific to cancer cells.

Location
Phone
212-610-0206
Clinical Expertise

Dermatology: Melanoma and Non-Melanoma Skin Cancers; Dermatology Consultations

Languages Spoken
English; French
Education

MD, Shiraz University Medical School (Iran)

Residencies

George washington University Hospital; University of Maryland Medical Center; Wayne State University Hospitals

Fellowships

Memorial Sloan Kettering Cancer Center; National Institutes of Health

Board Certifications

Dermatology

Publications by Bahar Dasgeb
Visit PubMed for full listing of Bahar Dasgeb journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.
View Bahar Dasgeb's laboratory research.